These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 7074600

  • 1. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA, Morgenstern B, Capizzi RL.
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [Abstract] [Full Text] [Related]

  • 2. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B, Capizzi RL, Kute TE, Morgan T, Dimling J.
    Cancer Res; 1989 Jun 15; 49(12):3259-66. PubMed ID: 2720678
    [Abstract] [Full Text] [Related]

  • 3. Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.
    Capizzi RL.
    Cancer Treat Rep; 1981 Jun 15; 65 Suppl 4():115-21. PubMed ID: 7049375
    [Abstract] [Full Text] [Related]

  • 4. Schedule-dependent synergism of combinations of hydroxyurea with adriamycin and 1-beta-D-arabinofuranosylcytosine with adriamycin.
    Ritch PS, Occhipinti SJ, Cunningham RE, Shackney SE.
    Cancer Res; 1981 Oct 15; 41(10):3881-4. PubMed ID: 7284997
    [Abstract] [Full Text] [Related]

  • 5. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
    Vadi H, Drewinko B.
    Cancer Res; 1986 Mar 15; 46(3):1105-9. PubMed ID: 3080232
    [Abstract] [Full Text] [Related]

  • 6. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
    Vaughan WP, Burke PJ.
    Cancer Res; 1983 May 15; 43(5):2005-9. PubMed ID: 6572561
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
    Grant S, Bhalla K, Rauscher F, Cadman E.
    Cancer Res; 1983 Nov 15; 43(11):5093-100. PubMed ID: 6577943
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells.
    Lauzon GJ, Paran JH, Paterson AR.
    Cancer Res; 1978 Jun 15; 38(6):1723-9. PubMed ID: 274174
    [Abstract] [Full Text] [Related]

  • 10. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
    Colly LP, Peters WG, Willemze R.
    Cancer Res; 1986 Aug 15; 46(8):3825-7. PubMed ID: 3460691
    [Abstract] [Full Text] [Related]

  • 11. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
    Taub JW, Huang X, Ge Y, Dutcher JA, Stout ML, Mohammad RM, Ravindranath Y, Matherly LH.
    Cancer Res; 2000 Nov 15; 60(22):6421-6. PubMed ID: 11103808
    [Abstract] [Full Text] [Related]

  • 12. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS, Chou TC, Andreeff M, Vale K, Clarkson BD, Young CW.
    Cancer Res; 1984 Feb 15; 44(2):825-30. PubMed ID: 6692380
    [Abstract] [Full Text] [Related]

  • 13. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
    Danhauser LL, Rustum YM.
    Cancer Res; 1985 May 15; 45(5):2002-7. PubMed ID: 3986756
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
    Burke PJ, Karp JE, Vaughan WP.
    J Natl Cancer Inst; 1981 Sep 15; 67(3):529-38. PubMed ID: 6944525
    [Abstract] [Full Text] [Related]

  • 15. Partial synchronization of L1210 cells by 5-fluorouracil and its use in drug combinations.
    Bhuyan BK, Blowers CL, Neil GL, Bono VH, Day KJ.
    Cancer Res; 1977 Sep 15; 37(9):3204-8. PubMed ID: 560250
    [Abstract] [Full Text] [Related]

  • 16. The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate.
    Edelstein M, Vietti T, Valeriote F.
    Cancer Res; 1975 Jun 15; 35(6):1555-8. PubMed ID: 1131822
    [Abstract] [Full Text] [Related]

  • 17. Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine.
    Neil GL, Berger AE, Bhuyan BK, DeSante DC.
    Cancer Res; 1976 Mar 15; 36(3):1114-20. PubMed ID: 56229
    [Abstract] [Full Text] [Related]

  • 18. Metabolism, incorporation into DNA, and interactions with 1-beta-D-arabinofuranosylcytosine of 5-hydroxymethyl-2'-deoxyuridine in human promyelocytic leukemia cells (HL-60).
    Vilpo JA, Vilpo LM.
    Cancer Res; 1988 Jun 01; 48(11):3117-22. PubMed ID: 3163271
    [Abstract] [Full Text] [Related]

  • 19. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice.
    Rauko P, Bauer W, Horvath Z, Höchtl T, Saiko P, Karl D, Schott H, Fritzer-Szekeres M, Novotny L, Szekeres T.
    Anticancer Res; 2003 Jun 01; 23(5A):3841-6. PubMed ID: 14666686
    [Abstract] [Full Text] [Related]

  • 20. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K, Nayak R, Grant S.
    Cancer Res; 1984 Nov 01; 44(11):5029-37. PubMed ID: 6091869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.